What the FDA labels say about taking them together
Oliceridine and rifampin
Oliceridine's FDA label of December 31, 2025 names rifampin in its drug interactions section; the rifampin label PlainMeds reads does not name oliceridine. The oliceridine label: “The concomitant use of OLINVYK and CYP3A4 inducers can decrease the plasma concentration of oliceridine, resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical …”
Check it at the source: the oliceridine FDA label on DailyMed (effective December 31, 2025, Trevena, Inc.); the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.).
What does the oliceridine label say about rifampin?
Oliceridine label, drug interactionsInducers of CYP3A4 Clinical Impact: The concomitant use of OLINVYK and CYP3A4 inducers can decrease the plasma concentration of oliceridine, resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to oliceridine.. … discontinued, consider OLINVYK dosage reduction and monitor for signs of respiratory depression. Examples: Rifampin, carbamazepine, phenytoin
Source: FDA drug label (OLINVYK), Trevena, Inc., effective December 31, 2025 (SPL set ce167984-8b9d-40b7-84ce-d0f33fff1eaa), via openFDA; the full label on DailyMed
What does the rifampin label say about oliceridine?
Rifampin's label (effective February 11, 2026) does not name oliceridine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Oliceridine | Rifampin | |
|---|---|---|
| Labeled for | Pain | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | $0.679 per capsule 300 mg capsule |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once